


What is claimed is:

1. A pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula




wherein R^1 is H or an optionally substituted hydrocarbon residue; R^2 is an optionally esterified carboxyl group; R^3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R^2 ; and Y is a bond, -O-, -S(O)_m- (wherein m is 0, 1 or 2) or -N(R^4)- (wherein R^4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.

2. The composition claimed in Claim 1, in which R^1 is an optionally substituted lower alkyl or lower cycloalkyl.
3. The composition claimed in Claim 2, in which R^1 is ethyl.
4. The composition claimed in Claim 1, in which R^1 is ethyl and Y is -O-.
5. The composition claimed in Claim 1, in which R^2 is a group represented by the -CO-D" (wherein D" stands for hydroxyl or a lower alkoxy whose alkyl moiety is optionally substituted with hydroxyl, amino, halogen, lower alkanoyloxy, lower cycloalkanoyloxy, lower alkoxycarbonyloxy, lower cycloalkoxycarbonyloxy or

6. The composition claimed in Claim 5, in which R^2 is a lower alkoxycarbonyl optionally substituted with cyclohexyloxycarbonyloxy.

8. The composition claimed in Claim 7, in which R^3 is



10. The composition claimed in Claim 8, in which R³ is 2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl.

12. The composition of Claim 1, in which R¹ is a lower alkyl and Y is -O-, R² is a lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy, and R³ is tetrazolyl.

14. The composition of Claim 1, in which the compound represented by the formula (I) is 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

15. The composition of Claim 1, in which the compound represented by the formula (I) is pivaloyloxymethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-

1H-benzimidazole-7-carboxylate.

16. The composition of Claim 1, in which the compound represented by the formula (I) is 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid.

17. The composition of Claim 1, in which the compound having diuretic activity is a member selected from the group consisting of amiloride, chlorothiazide, hydrochloride, benzthiazide, ticrynafen, acetazolamide, aminophylline, cyclothiazide, trichloromethiazide, cyclopentiazide, hydrochlorothiazide, methyclothiazide, benthylhydrochlorothiazide, penfluthiazide, ethiazide, hydroflumethiazide, polythiazide, chlorthalidone, chlorthalidone, cyclothiazide, bendroflumethiazide, meticrane, tripamide, metrazone, indapamide, quinethazone, furosemide, bumetanide, mefruside, azosemide, ethacrynic acid, sodium ethacrylate, piretanide, spironolactone, potassium canrenoate, quinethazone and triamterene.


18. The composition of Claim 1, in which the compound having calcium antagonistic activity is a member selected from the group consisting of diltiazem hydrochloride, teloridine hydrochloride, nicardipine hydrochloride, varnidipine hydrochloride, flunarizine hydrochloride, verapamil hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and benidipine.

19. The composition of Claim 1, in which the angiotensin II-mediated diseases include hypertension, cardiac insufficiency, ischemic peripheral circulation disturbances, myocardial ischemia, vein insufficiency, progressive cardiac insufficiency after myocardial infarction, diabetic nephritides, nephritis, arteriosclerosis, hyperaldosteronism, dermatosclerosis, glomerulosclerosis, renal insufficiency, diseases of

2025 RELEASE UNDER E.O. 14176

central nervous system, sensory disturbances including Alzheimer's disease, deficiency of memory, depression, amnesia and senile dementia, anxiety neurosis, catatonia or indisposition, glaucoma, intraocular high tension.

20. A method for the prophylaxis or treatment of angiotensin II-mediated diseases in a mammal in need thereof which comprises administering an effective amount of a compound having angiotensin II antagonistic activity represented by the formula (I)



wherein R^1 is H or an optionally substituted hydrocarbon residue; R^2 is an optionally esterified carboxyl group; R^3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R^2 ; and Y is a bond, -O-, -S(O)m- (wherein m is 0, 1 or 2) or -N(R^4)- (wherein R^4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with an effective amount of a compound having diuretic activity or a compound having calcium antagonistic activity.